Hayretin Yumerefendi

Company: Novartis AG

Job title: Associate Director & Group Leader

Seminars:

Roundtable Discussion: Addressing Safety Concerns in Fc-Targeted Therapies for Improved Patient Safety to Enhance Clinical Confidence 1:30 pm

• Investigating potential off-target effects and cytokine release syndromes to identify and mitigate potential safety risks to develop well-tolerated and safe Fc-based therapies • Implementing robust preclinical safety studies and clinical monitoring strategies to proactively address safety concerns to build clinical confidence in the use of Fc-targeted therapies • Analysing real-world safety data and patient-reported…Read more

day: Conference Day Two